Prevail Therapeutics Inc. (NASDAQ:PRVL) Short Interest Down 9.6% in January
Prevail Therapeutics Inc. (NASDAQ:PRVL) was the recipient of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 677,100 shares, a decrease of 9.6% from the January 15th total of 748,800 shares. Based on an average trading volume of 109,800 shares, the days-to-cover ratio is currently 6.2 days. Approximately 2.4% of the company’s shares are sold short.
Several large investors have recently bought and sold shares of the company. Bank of America Corp DE boosted its stake in shares of Prevail Therapeutics by 15.3% in the 4th quarter. Bank of America Corp DE now owns 277,281 shares of the company’s stock valued at $4,389,000 after purchasing an additional 36,821 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Prevail Therapeutics by 1.6% in the 4th quarter. Bank of New York Mellon Corp now owns 213,490 shares of the company’s stock valued at $3,380,000 after purchasing an additional 3,419 shares during the last quarter. State Street Corp boosted its stake in shares of Prevail Therapeutics by 68.8% in the 4th quarter. State Street Corp now owns 104,886 shares of the company’s stock valued at $1,660,000 after purchasing an additional 42,767 shares during the last quarter. BlackRock Inc. bought a new position in Prevail Therapeutics during the second quarter worth $1,320,000. Finally, Vanguard Group Inc. bought a new position in Prevail Therapeutics during the second quarter worth $1,015,000. 78.00% of the stock is currently owned by institutional investors.
Several brokerages have issued reports on PRVL. Zacks Investment Research cut shares of Prevail Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 14th. Cowen reaffirmed a “buy” rating on shares of Prevail Therapeutics in a research note on Tuesday, November 12th. Finally, Wedbush reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Prevail Therapeutics in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $16.50.
Prevail Therapeutics (NASDAQ:PRVL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.12). Equities analysts expect that Prevail Therapeutics will post -2.74 earnings per share for the current year.
About Prevail Therapeutics
Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.
Read More: How to invest using market indexes
Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.